Congress Park Capital LLC Has $4.48 Million Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Congress Park Capital LLC lowered its holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 17.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,035,617 shares of the biotechnology company's stock after selling 419,878 shares during the quarter. Heron Therapeutics comprises about 1.7% of Congress Park Capital LLC's investment portfolio, making the stock its 18th largest position. Congress Park Capital LLC owned 1.34% of Heron Therapeutics worth $4,478,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Nicolet Advisory Services LLC bought a new stake in shares of Heron Therapeutics during the fourth quarter valued at approximately $25,000. Argent Advisors Inc. bought a new position in Heron Therapeutics in the 4th quarter valued at $31,000. Focus Partners Wealth bought a new position in Heron Therapeutics in the 4th quarter valued at $31,000. State of Wyoming increased its stake in shares of Heron Therapeutics by 573.5% in the 4th quarter. State of Wyoming now owns 29,736 shares of the biotechnology company's stock valued at $45,000 after buying an additional 25,321 shares during the period. Finally, Cutter & CO Brokerage Inc. raised its position in shares of Heron Therapeutics by 69.6% during the fourth quarter. Cutter & CO Brokerage Inc. now owns 33,135 shares of the biotechnology company's stock worth $51,000 after acquiring an additional 13,600 shares during the last quarter. Institutional investors and hedge funds own 80.01% of the company's stock.

Heron Therapeutics Stock Up 2.6%

Shares of NASDAQ HRTX opened at $2.00 on Friday. Heron Therapeutics, Inc. has a twelve month low of $1.04 and a twelve month high of $3.73. The stock has a market cap of $305.12 million, a price-to-earnings ratio of -33.33 and a beta of 1.15. The company's fifty day moving average is $2.03 and its 200-day moving average is $1.92.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.02. The business had revenue of $38.90 million for the quarter, compared to analyst estimates of $37.08 million. On average, research analysts anticipate that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on HRTX. HC Wainwright began coverage on Heron Therapeutics in a research report on Monday, June 9th. They issued a "buy" rating and a $6.00 price objective for the company. Needham & Company LLC reiterated a "buy" rating and set a $4.00 price target on shares of Heron Therapeutics in a research report on Friday, April 11th. Finally, Wall Street Zen raised shares of Heron Therapeutics from a "hold" rating to a "buy" rating in a research note on Friday, June 6th.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.